Back to search results

GOCART Study: Improving Recovery After CAR-T Therapy for Older Adults

This study, called GOCART, is for people aged 60 and older with B-cell non-Hodgkin lymphoma or multiple myeloma who are receiving CAR-T therapy. It aims to see if a special program of care, guided by a geriatric assessment (a multi-dimensional health check covering physical function, thinking skills, and nutrition), can help you recover faster after CAR-T therapy compared to standard care. This program includes education on preventing delirium, nutritional support, and physical therapy. Researchers will measure changes in your physical abilities (using the Short Physical Performance Battery) from before treatment to 30 days after CAR-T infusion to see how well the program works. The study plans to enroll 164 participants.

Study design
This is an interventional study where participants are randomly assigned to one of two groups. It plans to enroll 164 participants.
What's involved
You would undergo a geriatric assessment, and depending on your assigned group, you might receive delirium prevention education, nutritional optimization, and physical therapy. The study measures changes from before treatment to 30 days after CAR-T infusion.
Compensation
Not stated in the trial record.
Follow-up
Your physical abilities will be assessed at 30 days after CAR-T infusion. Other measures, like quality of life, will be evaluated at 30 and 100 days, with overall survival tracked for one year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06052826

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

Recruiting
PHASE2Ages 60+InterventionalSupportive care
City of Hope Medical Center
~164 participants
Updated 2025-10-06 on ClinicalTrials.gov
What's tested:Best PracticeCognitive InterventionComprehensive Geriatric AssessmentNutritional InterventionPhysical TherapyQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in Short Physical Performance Battery (SPPB)
Measured over From baseline to day 30 after chimeric antigen receptor T-cell (CAR-T) infusion

Conditions

B-Cell Non-Hodgkin Lymphoma
Multiple Myeloma

Explore related trials

B-Cell Non-Hodgkin LymphomaMultiple Myeloma

NCT06052826

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Andrew S Artz · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Andrew S. Artz
[email protected]
626-218-2405
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to provide informed consent
Patient's physician must agree for patient participation. A physician may elect to provide blanket agreement for participation of any eligible CAR-T patient under their care
Ability to read English, or Spanish. Other languages will be acceptable with site principal investigator (PI) agreement if surveys are available and language does not preclude completing study procedures
Age: \>= 60 years at the time of enrollment
Scheduled to receive an Food and Drug Administration (FDA)-approved CAR-T for treatment of multiple myeloma or B-cell non- Hodgkin lymphoma
Willing and able to complete study requirements
Patients expect to be able to participate at least once before lymphodepletion with trimodality optimization visits

Exclusion

Prior CAR-T therapy
Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

What this trial measures

  • Changes in Short Physical Performance Battery (SPPB)From baseline to day 30 after chimeric antigen receptor T-cell (CAR-T) infusion

    T-test will be used to compare SPPB changes score between two arms at 30 days after CAR-T infusion.